The global market value of the tumor ablation market
was valued at USD 1.6 billion in 2022, and a CAGR of 10.1% is expected during
the forecast period. The increasing number of cancer patients all over the
world and the demand for tumor ablation devices by doctors are driving the
growth of the market significantly. The economic burden and rise in demand for
minimally invasive procedures to remove tumors are driving the growth of the
Reduced morbidity with these procedures is driving the
significance of minimally invasive procedures. Research and development
activities in the field of tumor ablation are driving the growth of the market.
Increasing awareness among people about chronic diseases is driving the market's
The COVID-19 pandemic, due to disruption in the supply
chain, stringent lockdown, and social distancing, had hampered the growth of
every industry. During the pandemic, there was a shift in priorities among the people;
people were too bothered by COVID-19. Hospitals all over the world during the
pandemic were occupied with the treatment of patients suffering from COVID-19.
The condition was worse for all the patients suffering from other diseases,
except COVID-19. Pandemics lead to a demand for minimally invasive procedures
to reduce the risk of exposure to the virus in healthcare settings. Tumor
ablation, being a minimally invasive option for certain cancers, saw increased
adoption during this time. There was a significant shift during remote health
monitoring and telemedicine, which accelerated the growth in the market. Many
non-urgent medical procedures were cancelled during the pandemic.
The increasing incidence of cancer globally is a major
driver for the tumor ablation market. As the incidence of various types of
cancer continues to increase, there is a growing demand for effective and
minimally invasive treatment options like tumor ablation. Ongoing advancements
in ablation technologies like radiofrequency ablation, microwave ablation,
cryoablation, and irreversible electroporation have improved treatment outcomes
and expanded the applicability of tumor ablation techniques. To a wider range
of cancer types and anatomical locations.
The increasing number of aging people
all over the world, who are more susceptible to cancer, is driving the growth
of the market. Ongoing research and development efforts are leading to the
introduction of innovative ablation technologies and techniques such as image-guided
ablation, robotic-assisted ablation, and combination therapies.
awareness about cancer prevention, early detection, and treatment options,
coupled with the implementation of cancer screening programs in many countries,
is driving the demand for the cancer ablation market. Favorable reimbursement
policies for tumor ablation procedures in many countries encourage patients and
healthcare providers to opt for these treatments. Increasing government
initiatives regarding cancer treatment and making people well aware of the
disease are driving significant growth in the market.
Middle East and
Market Application Segmentation
On the basis of application, the tumor ablation market
is segmented into kidney cancer, lung cancer, bone cancer, prostate cancer,
breast cancer, and liver cancer. Targeting various types of cancers falls under
the category of oncology, which is the leading segment and is expected to
dominate the market during the forecast period. It deals with pain caused by
tumors, especially for patients who are not suitable candidates for surgery.
Providing symptom relief and improving the quality of life for patients with
advanced cancer who are not eligible for curative treatments. This category
includes emerging applications or niche uses of tumor ablation technologies.
Market by Treatment Segmentation
On the basis of the treatment, the tumor ablation market
is segmented into surgical ablation, laparoscopic ablation, and percutaneous
ablation. Surgical ablation involves open surgery to remove or destroy the
tumor. It’s a more invasive approach, but it is necessary for larger or more
complex tumors. Laparoscopic procedures involve making small incisions and
using specialized instruments and a camera to visualize and treat the tumor.
It’s less invasive than open surgery and typically results in a faster recovery
time. This approach involves accessing the tumor through the skin using needles
or probes guided by imaging techniques such as ultrasound, CT, or MRI. Common
percutaneous techniques include radiofrequency ablation, microwave ablation,
cryoablation, and laser ablation. Percutaneous ablation is minimally invasive
and is often performed on an outpatient basis. The increasing number of cancer
patients worldwide is driving growth in the market.
On the basis of the regions, the tumor ablation market
is segmented into 5 parts: Asia Pacific, North America, Europe, Middle East and
Africa, and Latin America. Due to rising prevalence of cancer cases, North
America is expected to witness the highest percentage of revenue growth.
Increasing geriatric population in the region is the main cause of growth in
revenue in the region. Increasing awareness about the cancer treatment, and
increase in geriatric population is the main reason behind the growth in European
market significantly in the countries like Germany, England, Italy, Spain, and
France. Asia pacific region is diverse and dynamic, with varying economic,
political, and social landscapes across its countries.
like China, India, Japan, and South Korea play a significant role, While
Southeast Asian nations are emerging as a key player. Nations like Vietnam,
Indonesia and Malaysia are playing key roles in the market. Technologically
powerful countries like Singapore, and South Korea are leading in innovation.
Population growth, Urbanization, and environment sustainability, and social
inequality are major challenges. Overall Asia Pacific region remains crucial to
global dynamics. The presence of key players in North America, and Europe
region is the main cause behind the growth in the market. Middle East and Latin
America is witnessing moderate growth in the market due to less awareness about
Johnson and Johnson
Lifesciences Holding Corporation